Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia

← catalyst calendar

NCT06137118 · readout in 540 d

Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.

Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
255estimated
Sites
82
Countries
Australia, Brazil, Canada +10

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2023-12-29actualWhen the study began enrolling
Primary completion2028-02-11estimatedThe date the last participant is measured for the primary outcome — the readout window
Study completion2028-09-15estimatedThe whole study's end, after follow-up
First posted2023-11-18actualWhen this record first appeared on the registry
Results postedWhen the sponsor posted results to the registry
Record updated2026-08-19actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

  • B-cell Acute Lymphoblastic Leukemia (B-ALL)

Intervention

  • Drug: Surovatamig — also filed as AZD0486

Primary outcomes

what the primary-completion date above is the date OF
Part A: Frequency of DLTs
measured Up to 28 days
Parts A & B: Safety Evaluation of AZD0486
measured From signing of informed consent through data cutoff, up to 57 months
Parts B & C: Rate of CR within 3 cycles
measured Up to three cycles of 28 days each
Part D: CR/CRh within 3 cycles
measured Up to three cycles of 28 days each

Publications

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed